In 2011H1, operating revenue of Walvax Biotechnology reached RMB180 million, up 42.6% YoY; while its net income achieved RMB84 million, up 48.2% YoY. Meanwhile, HiB vaccine generated revenue of RMB140 million, up 36% YoY, and A+C-group epidemic cerebrospinal meningitis combined vaccine contributed revenue of RMB40.59 million, up 71% YoY. Revenue growth of these two kinds of vaccine highly enhanced the performance of Walvax.

It is estimated that the theoretical market sizes of HiB vaccine and A+C-group combined vaccine are 64 million units/year and 48 million units/year respectively. According to National Institutes for Food and Drug Control, lot release volumes of these two vaccines were 24.96 million units and 8.19 million units separately in 2010. With relatively lower popularizing rate of 39% and 17% currently, the growth potential is quite huge. Therefore, performance of Walvax will be definitely further enhanced backed by the sound development of these two vaccines.

Sales of Hib Vaccine and A+C-Group Epidemic Cerebrospinal Meningitis Combined Vaccine of Yunnan Walvax, 2009-2012 (RMB mln)

Source: Yunnan Walvax, ResearchInChina